Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Comparison of Visual Fields: Humphrey Field Analyzer (HFA) SITA Strategy, SCOPE (GATE Strategy) and Humphrey MATRIX Perimeter (X-SCOPE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01068938
Recruitment Status : Unknown
Verified December 2016 by Ulrich Schiefer, University Hospital Tuebingen.
Recruitment status was:  Active, not recruiting
First Posted : February 17, 2010
Last Update Posted : December 20, 2016
Information provided by (Responsible Party):
Ulrich Schiefer, University Hospital Tuebingen

Brief Summary:
The purpose of this study is to compare three perimetric techniques regarding progression of the visual field.

Condition or disease Intervention/treatment
Glaucoma Device: three different perimeters: HFA, Octopus, MATRIX

Layout table for study information
Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Detection of Visual Field Defects and Scotoma Progression in Glaucomatous Optic Neuropathy, Using Short-term Intervals With Automated Scotoma-oriented Perimetry (SCOPE) and the Fast Thresholding Strategy GATE (German Adaptive Threshold Estimation)
Study Start Date : November 2008
Actual Primary Completion Date : December 2013
Estimated Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma

Group/Cohort Intervention/treatment
open angle glaucoma, glaucoma suspects
risk of progression, Latanoprost monotherapy
Device: three different perimeters: HFA, Octopus, MATRIX
visual fields

Primary Outcome Measures :
  1. glaucoma progression [ Time Frame: 6 month ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
University Eye Hospital

Inclusion Criteria:

  • max. ± 8 dpt sph, max. ± 3 dpt cyl
  • distant visual acuity > 10/20
  • isocoria, pupil diameter > 3 mm
  • at least one risk of progression: optic disc (splinter) hemorrhage / cup to disc ratio (CDR) > 0.7 / inter-eye asymmetry of CDR >0.2 / notching of the optic disc /retinal nerve fibre layer (RNFL) defects / intraocular pressure( IOP) >22 mmHg / central corneal thickness < 520 µm / advanced visual field defect stage Aulhorn III / elder than 70 years

Exclusion Criteria:

  • pregnancy, nursing
  • diabetic retinopathy
  • asthma
  • HIV+ or AIDS
  • history of epilepsy or significant psychiatric disease
  • medications known to effect visual field sensitivity
  • infections (e.g. keratitis, conjunctivitis, uveitis)
  • severe dry eyes
  • miotic drug
  • amblyopia
  • squint
  • nystagmus
  • albinism
  • any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields,disc imaging or accurate IOP readings
  • keratoconus
  • intraocular surgery (except for uncomplicated cataract surgery) performed < 3 month prior to screening
  • history or signs of any visual pathway affection other than glaucoma
  • allergies with regard to topic glaucoma medication
  • history or presence of macular disease and / or macular edema
  • ocular trauma
  • medications known to affect visual field sensitivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01068938

Layout table for location information
Centre for Ophthalmology, Institute for Ophthalmic Research
Tuebingen, Germany, 72076
Sponsors and Collaborators
University Hospital Tuebingen
Layout table for investigator information
Principal Investigator: Ulrich Schiefer, MD Centre for Ophthalmology, Institute for Ophthalmic Research

Additional Information:
Layout table for additonal information
Responsible Party: Ulrich Schiefer, Prof. Dr. med., University Hospital Tuebingen Identifier: NCT01068938    
Other Study ID Numbers: X-SCOPE
116MIR08023 ( Other Grant/Funding Number: Pfizer )
428/2008BO1 ( Other Identifier: Ethics Committee University Hospital Tübingen )
First Posted: February 17, 2010    Key Record Dates
Last Update Posted: December 20, 2016
Last Verified: December 2016
Keywords provided by Ulrich Schiefer, University Hospital Tuebingen:
visual field
glaucoma progression
POAG and glaucoma suspects with prostaglandin monotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Ocular Hypertension
Eye Diseases